Dual Antiplatelet Therapy for ACS Without PCI
For patients with acute coronary syndrome not undergoing PCI, initiate dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) for at least 12 months, unless high bleeding risk dictates otherwise. 1
Drug Selection
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines establish clear preferences for P2Y12 inhibitor selection:
Ticagrelor or prasugrel are preferred over clopidogrel in ACS patients undergoing PCI, but this preference is specifically stated for the PCI population 1
For non-PCI ACS patients managed conservatively or with delayed invasive strategy (>24 hours), clopidogrel or ticagrelor may be considered as upstream treatment to reduce major adverse cardiovascular events 1
Ticagrelor demonstrates benefit irrespective of treatment strategy (invasive vs. conservative), making it a reasonable first-line choice even without PCI 2
Avoid prasugrel in patients with prior stroke/TIA (increased cerebrovascular events: 6.5% vs 1.2% with clopidogrel), age >75 years, or weight <60 kg 3
Dosing Regimen
Standard dosing for DAPT in ACS without PCI:
- Aspirin: Standard dose (specific dosing per institutional protocols)
- Clopidogrel: Loading dose followed by maintenance dosing
- Ticagrelor: Acts within 30 minutes (vs. 2 hours for clopidogrel) with superior platelet inhibition (high on-treatment residual platelet reactivity ~3% vs. 30-40% with clopidogrel) 3
Duration of Therapy
The default duration is at least 12 months for patients not at high bleeding risk 1, 3
Modifying Duration Based on Bleeding Risk:
High bleeding risk patients (≥4% annual risk of serious bleeding or ≥1% intracranial hemorrhage risk):
- Consider shorter duration (3-6 months) of DAPT 3
- High-risk features include: age ≥65 years, BMI <18.5, diabetes, prior bleeding, or concurrent oral anticoagulation 3
Low bleeding risk patients:
- Prolonged DAPT beyond 12 months may be considered, though optimal duration beyond 1 year remains unclear 3, 4
- For patients with previous MI completing 1 year of DAPT, continuing with reduced-dose ticagrelor 60 mg BID should be considered for up to 3 years in high-risk patients 2, 4
Bleeding Risk Mitigation Strategies
Even in non-PCI patients, implement these protective measures:
- Proton pump inhibitor is recommended for patients at risk for gastrointestinal bleeding 1
- Use risk scores (DAPT score, PRECISE-DAPT score) to support duration decisions, though these tools have limitations 2, 4
Critical Caveats
- The evidence base for DAPT duration and specific agent selection is stronger for PCI patients than for medically-managed ACS 3, 5
- No evidence supports DAPT for primary prevention or stable CAD without ACS 6
- DAPT increases bleeding risk in all populations—the benefit-risk balance must favor ischemic protection over bleeding hazard 3, 4, 6
- Recent evidence suggests discontinuing aspirin rather than the P2Y12 inhibitor may yield better outcomes, though this applies primarily to post-PCI populations 3